Developing powerful new treatments for HIV
Ultra-potent HIV capsid inhibitors
This study is looking at a new medication called GS-6207 that targets a key part of the HIV virus to help create longer-lasting treatments, making it easier for people living with HIV to manage their condition without needing to take daily pills.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10898753 on NIH RePORTER |
What this research studies
This research focuses on creating long-acting antiretroviral agents that target the HIV-1 capsid protein, which plays a crucial role in the virus's life cycle. By investigating a new drug called GS-6207, which has shown promising results in early clinical trials, the research aims to understand how this drug works and to develop even more effective second-generation inhibitors. The goal is to reduce the need for daily medication and combat drug-resistant strains of HIV, ultimately improving treatment adherence and patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who may benefit from new treatment options, especially those struggling with adherence to daily medication.
Not a fit: Patients who are not living with HIV or those who have already achieved viral suppression with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and convenient HIV treatments that require less frequent dosing.
How similar studies have performed: Previous research has shown success with similar approaches targeting the HIV capsid protein, indicating a promising avenue for further development.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Kvaratskhelia, Mamuka — University of Colorado Denver
- Study coordinator: Kvaratskhelia, Mamuka
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.